Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy

被引:4
|
作者
Jasmiad, Nurbadriah Binti [1 ]
Abd Ghani, Rohana Binti [1 ,2 ]
Agarwal, Renu [3 ]
Ismail, Zaliha Binti [4 ]
Abdullah, Azlindarita Aisyah Mohd [5 ,6 ]
Idorus, Mohd Yusri [7 ]
机构
[1] Univ Teknol MARA UiTM, Fac Med, Dept Internal Med, Sungai Buloh, Selangor Darul, Malaysia
[2] Univ Teknol MARA UiTM, Inst Pathol Lab & Forens Med I PPerForM, Sungai Buloh, Selangor Darul, Malaysia
[3] Int Med Univ, Sch Med, Dept Pharmacol & Therapeut, Kuala Lumpur, Malaysia
[4] Univ Teknol MARA UiTM, Fac Med, Dept Publ Hlth Med, Sungai Buloh, Selangor Darul, Malaysia
[5] MSU Med Ctr, Shah Alam, Selangor Darul, Malaysia
[6] Management & Sci Univ, MSU Clin Ctr Excellence, Shah Alam, Selangor Darul, Malaysia
[7] Univ Teknol MARA UiTM, Fac Med, Inst Med Mol Biotechnol IMMB, Sungai Buloh, Selangor Darul, Malaysia
关键词
Type 2 diabetes mellitus; Diabetic retinopathy; Tissue plasminogen activator (tPA); Plasminogen activator inhibitor-1 (PAI-1); INSULIN-RESISTANCE; OBESITY; PROTEINS; PARAMETERS; PAI-1;
D O I
10.1186/s12886-022-02550-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Diabetic retinopathy (DR) is a serious complication of longstanding type 2 diabetes mellitus (T2DM), a leading cause of blindness and visual disability in the world. The aim of this study is to compare the activity of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in tears and serum of patients with DR and those without DR. Method Among the T2DM patients enrolled in this study, 26 patients had DR (n = 26) while 29 were without DR (n = 29). The blood and tear samples were obtained from all participants. The level of PAI-1 and tPA were measured in both the serum and tears. Anthropometric measurements, HbA1c, renal and lipid profile were also obtained. Results Patients with DR had significantly longer disease duration and higher systolic blood pressure compared to those without DR. Serum PAI-1 level was significantly higher in patients with DR compared to those without DR, 32.72 (IQR 32.52) vs 21.37 (IQR 14.93) ng/mL, respectively (p < 0.05). However, tear PAI-1 were comparable in both groups. Serum and tear tPA levels in both groups were also comparable (p > 0.05). Among patients with DR, there were no significant correlations between tear and serum of both biomarkers. Patients without DR showed a moderate positive correlation between serum and tear tPA levels with a coefficient of 0.363, albeit no statistical significance. Patients with DR demonstrated a significant positive correlation between levels of tears PAI-1 and BMI (r = 0.555, p = 0.026). In the group without DR, there was a statistically significant positive correlation between serum level of PAI-1 with urine albumin creatinine ratio (UACR) (r = 0.501, p = 0.013). Conclusion The present study demonstrated a significantly greater serum PAI-1 levels in patients with DR compared to those without DR. No significant correlations between tears and serum PAI-1 and tPA were observed. Thus, the role of tear biomarkers remains relevant for further investigations.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Oligofructose Decreases Serum Lipopolysaccharide and Plasminogen Activator Inhibitor-1 in Adults with Overweight/Obesity
    Parnell, Jill A.
    Klancic, Teja
    Reimer, Raylene A.
    OBESITY, 2017, 25 (03) : 510 - 513
  • [32] Glucocorticoid-Responsive Tissue Plasminogen Activator (tPA) and Its Inhibitor Plasminogen Activator Inhibitor-1 (PAI-1): Relevance in Stress-Related Psychiatric Disorders
    Mennesson, Marie
    Revest, Jean-Michel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [33] Plasminogen Activator Inhibitor-1 and Diagnosis of the Metabolic Syndrome in a West African Population
    Kodaman, Nuri
    Aldrich, Melinda C.
    Sobota, Rafal
    Asselbergs, Folkert W.
    Brown, Nancy J.
    Moore, Jason H.
    Williams, Scott M.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (10):
  • [34] Increased concentration of plasminogen activator inhibitor-1 and fibrinogen in individuals with metabolic syndrome
    Palomo, Ivan G.
    Gutierrez, Cesar L.
    Alarcon, Marcelo L.
    Jaramillo, Julio C.
    Segovia, Fabian M.
    Leiva, Elba M.
    Mujica, Veronica E.
    Icaza, Gloria N.
    Diaz, Nora S.
    Moore-Carrasco, Rodrigo
    MOLECULAR MEDICINE REPORTS, 2009, 2 (02) : 253 - 257
  • [35] Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes
    Santos, KG
    Tschiedel, B
    Schneider, J
    Souto, K
    Roisenberg, I
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 61 (02) : 133 - 136
  • [36] Plasminogen Activator Inhibitor-1 and Adiponectin Are Associated With Metabolic Syndrome Components
    Vecchiola, Andrea
    Garcia, Killen
    Gonzalez-Gomez, Luis M.
    Tapia-Castillo, Alejandra
    Artigas, Rocio
    Baudrand, Rene
    Kalergis, Alexis M.
    Carvajal, Cristian A.
    Fardella, Carlos E.
    AMERICAN JOURNAL OF HYPERTENSION, 2022, 35 (04) : 311 - 318
  • [37] Negative correlation between D-dimer and plasminogen activator inhibitor-1 levels is absent in obese women
    Ceo, Priscilla T.
    Petruceli, Eveline
    Bosco, Adriana Ap.
    Andrade-Fernandes, Claudia M.
    Russi, Cristiane V. C.
    Carvalho, Maria das G.
    Sandrim, Valeria C.
    BLOOD COAGULATION & FIBRINOLYSIS, 2012, 23 (05) : 402 - 405
  • [38] Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
    Eriksson, P
    Reynisdottir, S
    Lönnqvist, F
    Stemme, V
    Hamsten, A
    Arner, P
    DIABETOLOGIA, 1998, 41 (01) : 65 - 71
  • [39] Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo
    Yudkin, JS
    Coppack, SW
    Bulmer, K
    Rawesh, A
    Mohamed-Ali, V
    THROMBOSIS RESEARCH, 1999, 96 (01) : 1 - 9
  • [40] Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
    P. Eriksson
    S. Reynisdottir
    F. Lönnqvist
    V. Stemme
    A. Hamsten
    P. Arner
    Diabetologia, 1998, 41 : 65 - 71